23 Jun 2025
Liquidators seek buyers for assets of Isansys Lifecare Ltd
Nick Harris and Lucinda Coleman, in the restructuring team at PKF Francis Clark, have been appointed liquidators of Isansys Lifecare Ltd, a pioneering UK-based medical technology company known for its innovative patient monitoring systems.
Founded in 2010, Oxfordshire-based Isansys Lifecare developed and marketed advanced wireless wearable sensors and data analytics platforms designed to improve patient outcomes and enable continuous monitoring both in hospitals and at home.
Early successes included government grants and positive clinical trials. In 2020, the company achieved over £1 million in sales, fuelling optimism that demand for its technology was set to soar. However, the Covid-19 pandemic impacted on the pace of adoption in the UK, Europe and US.
“Isansys Lifecare had an excellent reputation in the MedTech sector, and we are seeing significant interest in the company’s intellectual property assets from a range of parties,” said Nick. “Sadly, it was not possible to rescue the company as a going concern and there was no alternative to liquidation. Our focus now is on realising the assets of the company in order to deliver a return to creditors.”
The company’s assets include valuable intellectual property, research and development assets and a recently signed licensing agreement. Specialist agents Simon Bamford and Benoit Geurts, of Gordon Brothers, and legal adviser Andrew Knox, of Stephens Scown, are assisting the liquidators in the asset realisation process.
Creditors and parties interested in acquiring the company’s assets are encouraged to contact Nick Harris or Charles Bell at PKF Francis Clark’s Bristol office as soon as possible.
Isansys Lifecare Ltd entered creditors’ voluntary liquidation following sustained financial challenges, including high fixed costs typical of regulated medical device companies, leading to the exhaustion of investor and director funding. The company was unable to secure the additional investment needed to continue operations.
For further information or to express interest in the company’s assets, please contact Charles Bell on 0117 403 9800 or [email protected].
